Additionally, SGLT2i can lower HbA1c levels by 0.5-1.0% and support weight loss ( Studies have indicated that increased expression of the sodium-hydrogen exchanger isoform 1 (NHE-1) is linked to heart failure and may contribute to the development of hypertrophy and cardiac injury during ischemia and reperfusion ( Of note, long-term use of SGLT2i may lead to a reduction in glycosuric efficacy, without a corresponding decline in cardiovascular benefits
For the titration period data, CGM outcomes, insulin requirements and carbohydrate intake were manually input from the pumps and CGM commercial software into a secure database
It also revealed stellar effects on weight, with patients on the highest dose losing 22.9% of their body weight on average over that period, while those on placebo shed 2.1%
Incorporating dietary fibers, hydrating adequately, and engaging in physical activity can mitigate the effects of this side effect
Themes continuing from 2025 into 2026 As the obesity market moves into its acceleration phase, several trends that gained traction in 2025 will continue to influence strategies and market dynamics in 2026: As the obesity market evolves, there is a growing recognition that use of obesity medications to maintain weight will be critical for many people
Experts say the era of widespread compounded weight loss drugs has ended
